-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lorlatinib is an effective brain-penetrating third-generation ALK tyrosine kinase inhibitor (TKI), which has significant anti-tumor activity against ALK-positive non-small cell lung cancer ( NSCLC ).
NSCLC
This study evaluated the overall, intracranial and extracranial efficacy of loratinib for advanced ALK-positive NSCLC after treatment with second-generation ALK TKIs.
This study evaluated the overall, intracranial and extracranial efficacy of loratinib for advanced ALK-positive NSCLC after treatment with second-generation ALK TKIs.
In the ongoing phase II study (NCT01970865), patients with ALK-positive advanced NSCLC who had received more than one second-generation ALK TKI±chemotherapy were included in the extended cohort (EXP) based on treatment history.
Among the 139 patients who had been treated with the second-generation ALK TKI (EXP3B-5) for one or more times, 28 patients had received the second-generation ALK TKI (EXP3B) once, and 65 patients had received the ALK TKI (EXP4) twice.
In the cohort of patients treated with EXP3B-5, the ORR (95%CI) was 39.
In the cohort of patients treated with EXP3B-5, the ORR (95%CI) was 39.
In the EXP3B treatment cohort, ORR was 42.
In the EXP3B treatment cohort, ORR was 42.
In the EXP4-5 treatment cohort, ORR was 38.
In the EXP4-5 treatment cohort, ORR was 38.
Loratinib has clinically significant intracranial and extracranial anti-tumor activity in ALK-positive NSCLC patients who have progressed after the second-generation ALK TKI treatment, and both intracranial and extracranial ORR have increased, especially for patients with fewer previous treatments.
Loratinib has clinically significant intracranial and extracranial anti-tumor activity in ALK-positive NSCLC patients who have progressed after the second-generation ALK TKI treatment, and both intracranial and extracranial ORR have increased, especially for patients with fewer previous treatments.
Original source:
Felip E,Shaw AT,Bearz A et al.
org/10.
1016/j.
annonc.
2021.
02.
012">Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs in this message
